OIM
OPTN

Oracle Investment Management’s OptiNose OPTN Stock Holding History

Oracle Investment Management’s Portfolio OPTN Stock Details OPTN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-21,667
Closed -$475K – 25
2024
Q1 		$475K Buy
+21,667
New +$481K 0.32% 24

Other funds holding OPTN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MP
MVM Partners Boston, Massachusetts $10.8M AUM 61.97% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Oracle Investment Management's OPTN Position: Q2 2024 in Review

Oracle Investment Management sold out of OptiNose (OPTN) in Q2 2024, closing a stake of 21,667 shares — an estimated $475K sold.

Oracle Investment Management first reported a position in OPTN in Q1 2024 and held it in 1 quarter. The position peaked at $475K in Q1 2024. 84 funds tracked by Wall St. Rank hold OPTN as of Q2 2024.

  • Oracle Investment Management reported no remaining OptiNose position as of Q2 2024 after selling out during the quarter.
  • Oracle Investment Management sold 21,667 OptiNose shares in Q2 2024, an estimated $475K.
  • Oracle Investment Management first reported a position in OptiNose in Q1 2024 and held it in 1 quarter.
  • Oracle Investment Management's OptiNose position peaked at $475K in Q1 2024.
  • 84 funds tracked by Wall St. Rank held OptiNose as of Q2 2024.

Based on Oracle Investment Management's 13F filing for Q2 2024, filed 14 Aug 2024.